Krystal Biotech exhibits very strong recent price momentum with the stock closing at a new 52-week high and well above key moving averages, while several momentum indicators signal an overbought condition. On the fundamental side, the company shows high margins, positive earnings, and solid free cash flow generation with a net cash position, though revenue growth is modest and operating cash flow has recently declined. Short interest is elevated with nearly 10% of shares sold short and a high short-volume ratio, indicating active bearish positioning alongside a broadly positive news tone.